Editas Medicine Investor Relations Material
Latest events
Strategy Update
Editas Medicine
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Editas Medicine Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Collaboration and other research and development revenues
Expenses by
Financials
Editas Medicine, a genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company seeks to address the fundamental flaws in existing approaches to genetic and infectious diseases by developing TALEN and CRISPR genome editing systems that function more efficiently than existing technologies. It has invented lymphocyte-directed gene therapy that uses CRISPR/Cas9 technology to manufacture a novel endonuclease. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Key slides for Editas Medicine Inc
Strategy Update
Editas Medicine Inc
Corporate Presentation
Editas Medicine Inc
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
EDIT
Country
🇺🇸 United States